文献速递胸部肿瘤乳腺癌

Taselisib(一种口服PI3K抑制剂)在晚期实体瘤患者中的I期剂量递增研究

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
PubMed 文献 · Cancer Discov · 2017-03-22

这项I期研究采用改良3+3剂量递增设计,纳入34例局部晚期或转移性实体瘤患者,接受3–16 mg每日一次胶囊口服Taselisib。药代动力学呈剂量比例,平均半衰期为40小时;12和16 mg剂量水平观察到剂量限制性毒性。PIK3CA突变且可测量肿瘤患者的确认缓解率为36%(5/14),无已知PIK3CA热点突变者为0%(0/15)。

要点

  • Taselisib药代动力学呈剂量比例,平均半衰期为40小时。
  • 12和16 mg剂量水平观察到剂量限制性毒性,且第1周期剂量限制性毒性评估窗后出现更高级别不良事件累积。
  • PIK3CA突变可测量肿瘤患者确认缓解率为36%(5/14),无已知PIK3CA热点突变者为0%(0/15)。

核心结论

  • 初步数据与临床前数据一致,提示Taselisib在PIK3CA突变肿瘤患者中较无已知激活型PIK3CA热点突变肿瘤患者具有更强的抗肿瘤活性,且从最低测试剂量3 mg开始即出现缓解,支持Taselisib对PIK3CA突变肿瘤具有更高效力。

研究设计与样本

  • I期研究,采用改良3+3剂量递增设计,5个队列,34例局部晚期或转移性实体瘤患者接受3–16 mg每日一次胶囊口服Taselisib。

主要发现

  • Taselisib药代动力学呈剂量比例,平均半衰期为40小时。
  • 常见剂量依赖性治疗相关不良事件包括腹泻、高血糖、食欲下降、恶心、皮疹、口腔炎和呕吐。
  • 12和16 mg剂量水平观察到剂量限制性毒性,且第1周期剂量限制性毒性评估窗后出现更高级别不良事件累积。
  • 药效学显示患者肿瘤样本中≥3 mg即出现通路抑制,与临床前PIK3CA突变肿瘤异种移植模型一致。
  • PIK3CA突变且可测量肿瘤患者的确认缓解率为36%(5/14:4例乳腺癌,其中3例在12 mg;1例非小细胞肺癌),缓解从3 mg开始出现;无已知PIK3CA热点突变肿瘤患者为0%(0/15)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Taselisib is a potent and selective tumor growth inhibitor through PI3K pathway suppression. Thirty-four patients with locally advanced or metastatic solid tumors were treated (phase I study, modified 3+3 dose escalation; 5 cohorts; 3-16 mg taselisib once-daily capsule). Taselisib pharmacokinetics were dose-proportional; mean half-life was 40 hours. Frequent dose-dependent, treatment-related adverse events included diarrhea, hyperglycemia, decreased appetite, nausea, rash, stomatitis, and vomiting. At 12 and 16 mg dose levels, dose-limiting toxicities (DLT) were observed, with an accumulation of higher-grade adverse events after the cycle 1 DLT assessment window. Pharmacodynamic findings showed pathway inhibition at ≥3 mg in patient tumor samples, consistent with preclinical PIK3CA-mutant tumor xenograft models. Confirmed response rate was 36% for PIK3CA-mutant tumor patients with measurable disease [5/14: 4 breast cancer (3 patients at 12 mg); 1 non-small cell lung cancer], where responses started at 3 mg, and 0% in patients with tumors without known PIK3CA hotspot mutations (0/15).Significance: Preliminary data consistent with preclinical data indicate increased antitumor activity of taselisib in patients with PIK3CA-mutant tumors (in comparison with patients with tumors without known activating PIK3CA hotspot mutations) starting at the lowest dose tested of 3 mg, thereby supporting higher potency for taselisib against PIK3CA-mutant tumors. Cancer Discov; 7(7); 704-15. ©2017 AACR.See related commentary by Rodon and Tabernero, p. 666This article is highlighted in the In This Issue feature, p. 653.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Juric D, Krop I, Ramanathan RK, et al. Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Cancer Discov. 2017. PMID: 28331003. doi:10.1158/2159-8290.CD-16-1080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。